Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy

Advanced Drug Delivery Reviews

Volumn 31, Issue 1-2, 1998, Pages 89-104

  Chari, Ravi V J ^a  

^a IMMUNOGEN INC   (United States)

Author keywords

Anti cancer agents; Antibody drug conjugates; Cancer; Prodrugs

Indexed keywords

ANTIBODIES; ONCOLOGY;

ANTIBODY DRUG CONJUGATES; PRODRUGS;

CONTROLLED DRUG DELIVERY;

ANTIBODY; ANTINEOPLASTIC AGENT; PRODRUG;

ANTIBODY AFFINITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONJUGATE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL;

EID: 0032489812     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00095-1     Document Type: Review

References (66)

1. Frei E. Combination cancer therapy: Presidential address. Cancer Res. 32:1972;2593-2607.
2. Kohler G., Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 256:1975;495-497.
3. Fleisher D., Bong R., Stewart B.H. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Adv. Drug Deliv. Rev. 19:1996;115-130.
4. Kearney A.S. Prodrugs and targeted drug delivery. Adv. Drug Deliv. Rev. 19:1996;225-239.
5. Boyer C.M., Lodor Y., Lottich S.C., Bast R.C. Jr. Antigenic cell surface markers in human solid tumors. Antibody Immunoconj. Radiopharmaceut. 1:1988;105-116.
6. A.M. Carroll, M.I. Greene, Tumor cell biology: tumor specific and associated antigens, in: M.R. Zalutsky (Ed.), Antibodies in Radiodiagnosis and Therapy. CRC, Boca Raton, FL, 1989, pp. 13-43.
7. Thielemans K., Maloney D.G., Meeker T., Fujimoto J., Doss C., Warnke R.A., Bind J., Gralow K., Miller R.A., Levy R. Strategies for production of monoclonal anti-idiotype antibodies against B-cell lymphomas. J. Immunol. 133:1984;495-501.
8. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastaic breast cancer. J. Clin. Oncol. 14:1996;737-744.
9. Roguska M.A., Pedersen J.T., Keddy C.A., Henry A.H., Searle S.J., Lambert J.M., Goldmacher V.S., Blättler W.A., Rees A.R., Guild B.C. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl. Acad. Sci. USA. 91:1994;969-973.
10. Roguska M.A., Pedersen J.T., Henry A.H., Searle S.M.J., Roja C.M., Avery B., Hoffee M., Cook S., Lambert J.M., Blattler W.A., Rees A.R., Guild G.C. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng. 9:1996;895-904.
11. Yokota T., Milenic D.E., Whitlow M., Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:1992;3402-3408.
12. Yokota T., Milenic D.E., Whitlow M., Wood J.F., Hubert S.L., Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res. 53:1993;3776-3783.
13. King D.J., Turner A., Farnsworth A.P.H., Adair J.R., Owens R.J., Pedley R.B., Baldock D., Proudfoot K.A., Lawson A.D.G., Beeley N.R.A., Millar K., Millican T.A., Boyce B.A., Antoniw P., Mountain A., Begent R.H.J., Shochat D., Yarranton Y.T. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54:1994;6176-6185.
14. A.L. Harris, D. Neal, Epidermal growth factor and its receptor in human cancer, in: M. Sluyser (Ed.), Growth Factors and Oncogenes in Breast Cancer. VCH, Chichester, 1987, pp. 60-90.
15. Harris A.L. The epidermal growth factor receptor as a target for therapy. Cancer Cells. 2:1990;321-323.
16. Carpenter G., Cohen H. Epidermal growth factor. Ann. Rev. Biochem. 48:1979;194-216.
17. Massague J. Transforming growth factor-α J. Biol. Chem. 265:1990;21393-21396.
18. Varga J.M., Asato N., Lande S., Lerner A.B. Melanotropin-daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells. Nature. 267:1977;56-58.
19. J.M. Varga, Hormone-drug conjugates, in: Methods in Enzymology, Academic Press 112, 1985, pp. 259-269.
20. McIntyre G.D., Scott C.F., Ritz J., Blättler W.A., Lambert J.M. Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents. Bioconjugate Chem. 5:1994;88-97.
21. Endo N., Takeda Y., Kishida K., Kato Y., Saito M., Umemoto N., Hara T. Target-selective cytotoxicity of methotrexate conjugated with monoclonal anti-MM46 antibody. Cancer Immunol. Immunother. 25:1987;1-6.
22. Pimm M.V., Paul M.A., Ogumuyiwa Y., Baldwin R.W. Biodistribution and tumor localization of a daunomycin-monoclonal antibody conjugate in nude mice with human tumor xenografts. Cancer Immunol. Immunother. 27:1988;267-271.
23. Spearman M.E., Goodwin R.M., Apelgren L.D., Bumol T.F. Disposition of the monoclonal antibody-Vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine (DAVLB) in tumor-bearing nude mice. J. Pharmacol. Exp. Ther. 241:1987;695-703.
24. Kato Y., Tsukada Y., Hara T., Hirai H. Enhanced anti-tumor activity of mitomycin C conjugated with anti-α-fetoprotein antibody by a novel method of conjugation. J. Appl. Biochem. 5:1983;313.
25. Smyth M.J., Foster H.M., Andrew S.M., Teh J.G., Krauer K., McKenzie I.F.C., Pietersz G.A. Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin-monoclonal antibody conjugates. Immunol. Cell Biol. 71:1993;167-179.
26. Smyth M.J., Pietersz G.A., McKenzie I.F.C. Selective enhancement of anti-tumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. Cancer Res. 47:1987;62-69.
27. Pietersz G.A., Krauer K. Antibody-targeted drugs for the therapy of cancer. J. Drug Targeting. 2:1994;183-215.
28. M. Sela, E. Hurwitz, Conjugates of antibodies with cytotoxic drugs, in: C.W. Vogel (Ed.), Immunoconjugates, Oxford University Press, New York, 1987, pp. 189-216.
29. Pietersz G.A. The linkage of cytotoxic drugs to antibodies for the treatment of cancer. Bioconjugate Chem. 1:1990;89-95.
30. Hurwitz E., Wilchek M., Pitha J. Soluble macromolecules as carriers for daunorubicin. J. Appl. Biochem. 2:1980;25-35.
31. Endo N., Takeda Y., Umemoto N., Kishida K., Watanabe K., Saito M., Kato Y., Hara T. Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates. Cancer Res. 48:1988;3330-3335.
32. Trouet A., Masquelier M., Baurain R., Campeneere D.D.-D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA. 79:1982;626-629.
33. Umemoto N., Kato Y., Endo N., Takeda Y., Hara T. Preparation and in vitro evaluation of a methotrexate-anti-MM46 monoclonal antibody conjugate via an oligopeptide spacer. Int. J. Cancer. 43:1989;677-684.
34. Shen W.-C., Ryser H.J.-P. cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 102:1981;1048-1054.
35. Yang H.M., Reisfeld R.A. Pharmacokinetics and mechanism of action of a doxorubicin-monoclonal 9.2.27 conjugate directed to a human melanoma proteoglycan. J. Natl. Cancer Inst. 80:1988;1154-1157.
36. Dillman R.O., Johnson D.E., Shawler D.L., Koziol J.A. Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug. Cancer Res. 48:1988;6097-6102.
37. Laguzza B.C., Nichols C.L., Briggs S.L., Cullinan D.J., Johnson D.A., Starling J.J., Baker A.l., Bumol T.F., Corvalan J.R.F. New antitumor monoclonal antibody-Vinca conjugate LY203725 and related compounds: design, preparation and representative in vivo activity. J. Med. Chem. 32:1989;548-555.
38. Greenfield R.S., Kaneko T., Daues A., Edson M.A., Fitzgerald K.A., Olech L.J., Grattan J.A., Spitalny G.L., Braslawsky G.R. Evaluation in vitro of adriamycin immunoconjugates synthesized using an acid-sensitive hydrazone link. Cancer Res. 50:1990;6600-6607.
39. Daussin F., Boschetti E., Delmotte F., Monsigny M. p-Benzylthiocarbamoyl-aspartyl-daunorubicin-substituted polytrisacryl. A new drug acid-labile arm-carrier conjugate. Eur. J. Biochem. 176:1988;625-628.
40. Singh M., Ghose T., Kralovec J., Blair A.H., Belitsky P. Inhibition of human renal cancer by monoclonal antibody-linked methotrexate in an ascites tumor model. Cancer Immunol Immunother. 32:1991;331-334.
41. Johnson I.S., Spearman M.E., Todd G.C., Zimmerman J.L., Bumol T.F. Monoclonal antibody-drug conjugates for site-directed chemotherapy: preclinical pharmacology and toxicology studies. Cancer Treatment Revs. 14:1987;193-196.
42. Trail P.A., Willner D., Knipe J., Henderson A.J., Lasch S.J., Zoekler M.E., Trailsmith M.D., Doyle T.W., King H.D., Casazza A.M., Braslawsky G.R., Brown J., Hofstead S.J., Greenfield R.S., Firestone R.A., Mosure K., Kadow K.F., Yang M.B., Hellstrom K.E., Hellstrom I. Effect of linker variation on the stability, potency and efficacy of carcinoma-reactive BR64-Doxorubicin immunoconjugates. Cancer Res. 57:1997;100-105.
43. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellstrom I., Hellstrom K.E. Cure of xenografted human carcinomas by BR96-Doxorubicin immunoconjugates. Science. 261:1993;212-215.
44. Froesch B.A., Stahel R.A. Preparation and functional evaluation of new doxorubicin immunoconjugates containing an acid-sensitive linker on small cell lung cancer. Cancer Immunol. Immunother. 42:1996;55-63.
45. Barbour N.P., Paborji M., Alexander T.C., Coppola W.P., Bogardus J.P. Stabilization of chimeric BR96-Doxorubicin immunoconjugates. Pharm. Res. 12:1995;215-222.
46. Uadia P., Blair A.H., Ghose T. Tumor and tissue distribution of a methotrexate-anti-EL4 immunoglobulin conjugate in EL4 lymphoma-bearing mice. Cancer Res. 44:1984;4263-4266.
47. Yang H.M., Reisfeld R.A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc. Natl. Acad. Sci. USA. 85:1988;1189-1193.
48. Braslawsky G.R., Edson M.A., Pearce W., Kaneko T., Greenfield R.S. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing. Cancer Res. 50:1990;6608-6614.
49. Aboud-Pirak E., Hurwitz E., Bellot F., Schlessinger J., Sela M. Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibody to epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA. 86:1989;3778-3781.
50. Starling J.J., Maciak R.S., Hinson N.A., Nichols C.L., Briggs S.L., Laguzza B.C. In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody. Cancer Immunol Immunother. 28:1989;171-178.
51. Apelgren L.D., Zimmerman D.L., Bruggs S.L., Bumol T.F. Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer. Cancer Res. 50:1990;3540-3544.
52. Elias D.J., Hirschowitz L., Kline L.E., Kroener J.F., Dillman R.O., Walker L.E., Robb J.A., Timms R.M. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1-4-methotrexate immunoconjugate in patients with non-small cell lung carcinoma. Cancer Res. 50:1990;4154-4159.
53. Elias D.J., Kline L.E., Robbins B.A., Johnson H.C.L., Pekny K., Benz M., Robb J.A., Walker L.E., Kosty M., Dillman R.O. Monoclonal antibody KS1-4-methotrexate immunoconjugate studies in non-small cell lung carcinoma. Am. J. Respir. Crit. Care Med. 150:1994;1114-1122.
54. Schneck D., Butler F., Dugan W., Littrell D., Petersen B., Bowsher R., DeLong A., Dorrbecker S. Disposition of a murine monoclonal antibody-Vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinoma. Clin. Pharmacol, Ther. 47:1990;36-41.
55. Schneck D., Butler F., Dugan W., Littrell D., Dorrbecker S., Petersen B., Bowsher R., DeLong A., Zimmerman J. Phase I studies with a murine monoclonal antibody-Vinca conjugate (KS1-4-DAVLB) in patients with adenocarcinoma. Antibody Immunoconjugates and Radiopharm. 2:1989;93-100.
56. Grasela D., LoBuglio A., Murray J.L., Raymond R., Birkhofer M., Summerill R., Stewart M. Parametric model for BR96-doxorubicin pharamacokinetics (PK) in cancer patients. Proc. Am. Assoc. Cancer Res. 36:1995;1393.
57. H.-H. Sedlacek, G. Seemann, D. Hoffmann, J. Czech, P. Lorenz, C. Kolar, K. Bosslet, in: Antibodies as carriers of cytotoxicity. H. Huber, W. Queiber (Eds.), Contrib. Oncology, Karger, Basel, 43, 1992, pp. 75-82.
58. Liu C., Tadayoni B.M., Bourret L.A., Mattocks K.M., Derr S.M., Widdison W.C., Kedersha N.L., Ariniello P.D., Goldmacher V.S., Lambert J.M., Blättler W.A., Chari R.V.J. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc. Natl. Acad. Sci. USA. 93:1996;8618-8623.
59. Chari R.V.J., Martell B.A., Gross J.L., Cook S.B., Shah S.A., Blättler W.A., McKenzie S.J., Goldmacher V.S. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res. 52:1992;127-131.
60. Chari R.V.J., Jackel K.A., Bourret L.A., Derr S.M., Tadayoni B.M., Mattocks K.M., Shah S.A., Liu C., Blättler W.A., Goldmacher V.S. Enhancement of the selectivity and anti-tumor activity of a CC-1065 analogue through immunoconjugate formation. Cancer Res. 55:1995;4079-4084.
61. Hinman L.M., Hamaan P.R., Wallace R., Menendez A.T., Durr F.E., Upeslacis J. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res. 53:1993;3536-3542.
62. Mueller B.M., Wrasidlo W.A., Reisfeld R.A. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjugate Chem. 1:1990;325-330.
63. Remillard S., Rebhun L.I., Howie G.A., Kupchan S.M. Antimitotic activity of the potent tumor inhibitor maytansine. Science. 189:1977;1002-1005.
64. Reynolds V.L., McGovren J.P., Hurley L.H. The chemistry, mechanism of action and biological properties of CC-1065; a potent antitumor antibiotic. J. Antibiot. 39:1986;319-334.
65. Lee M.D., Ellestad G.A., Borders D.B. Calicheamicins: discovery, structure, chemistry, and interaction with DNA. Acc. Chem. Res. 24:1991;235-243.
66. a epitope on distinct core proteins. J. Biol. Chem. 206:1991;21537-21547.